Palmitoylethanolamide attenuates neurodevelopmental delay and early hippocampal damage following perinatal asphyxia in rats

Palmitoylethanolamide attenuates neurodevelopmental delay and early hippocampal damage following perinatal asphyxia in rats

Impaired gas exchange close to labor causes perinatal asphyxia (PA), a neurodevelopmental impairment factor. Palmitoylethanolamide (PEA) proved neuroprotective in experimental brain injury and neurodegeneration models. This study aimed to evaluate PEA effects on the immature-brain, i.e., early neuro...

Full description

Bibliographic Details
Main Authors:	Maria I. Herrera, Lucas D. Udovin, Tamara Kobiec, Nicolas Toro-Urrego, Carlos F. Kusnier, Rodolfo A. Kölliker-Frers, Juan P. Luaces, Matilde Otero-Losada, Francisco Capani
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-08-01
Series:	Frontiers in Behavioral Neuroscience
Subjects:	PEA palmitoylethanolamide perinatal asphyxia neuroprotection hippocampal CA1 area reflexes
Online Access:	https://www.frontiersin.org/articles/10.3389/fnbeh.2022.953157/full

Similar Items

Corrigendum: Palmitoylethanolamide attenuates neurodevelopmental delay and early hippocampal damage following perinatal asphyxia in rats
by: Maria I. Herrera, et al.
Published: (2022-12-01)

Partial Reversal of Striatal Damage by Palmitoylethanolamide Administration Following Perinatal Asphyxia
by: Lucas D. Udovin, et al.
Published: (2020-01-01)

Palmitoylethanolamide Ameliorates Hippocampal Damage and Behavioral Dysfunction After Perinatal Asphyxia in the Immature Rat Brain
by: María I. Herrera, et al.
Published: (2018-03-01)

Synaptoprotection in Perinatal Asphyxia: An Experimental Approach
by: María Inés Herrera, et al.
Published: (2020-09-01)

PARTIAL NEUROPROTECTION FROM NEURODEVELOPMENTAL IMPAIRMENT BY ENVIRONMENTAL ENRICHMENT IN EXPERIMENTAL PERINATAL ASPHYXIA
by: Tamara Kobiec, et al.
Published: (2023-10-01)

Corrigendum: Neuroprotection in metabolic syndrome by environmental enrichment. A lifespan perspective
by: Tamara Kobiec, et al.
Published: (2023-09-01)

Neuroprotection in metabolic syndrome by environmental enrichment. A lifespan perspective
by: Tamara Kobiec, et al.
Published: (2023-08-01)

Interleukin-1 Links Autoimmune and Autoinflammatory Pathophysiology in Mixed-Pattern Psoriasis
by: Rodolfo Kölliker Frers, et al.
Published: (2021-01-01)

Multidimensional overview of neurofilament light chain contribution to comprehensively understanding multiple sclerosis
by: Rodolfo A. Kölliker Frers, et al.
Published: (2022-07-01)

Could Perinatal Asphyxia Induce a Synaptopathy? New Highlights from an Experimental Model
by: María Inés Herrera, et al.
Published: (2017-01-01)

Therapeutic benefit of palmitoylethanolamide in the management of neuropathic pain
by: I. D. Chaurasia, et al.
Published: (2018-12-01)

TIME COURSE MODIFICATIONS INDUCED BY PERINATAL ASPHYXIA IN RAT CNS
by: Francisco Capani, et al.
Published: (2015-04-01)

Neuroinflammation: An Integrating Overview of Reactive-Neuroimmune Cell Interactions in Health and Disease
by: Rodolfo Kölliker-Frers, et al.
Published: (2021-01-01)

Effects of Palmitoylethanolamide (PEA) on Nociceptive, Musculoskeletal and Neuropathic Pain: Systematic Review and Meta-Analysis of Clinical Evidence
by: Damiana Scuteri, et al.
Published: (2022-08-01)

Palmitoylethanolamide and Related ALIAmides: Prohomeostatic Lipid Compounds for Animal Health and Wellbeing
by: Enrico Gugliandolo, et al.
Published: (2020-06-01)

A Decades-Long Journey of Palmitoylethanolamide (PEA) for Chronic Neuropathic Pain Management: A Comprehensive Narrative Review
by: Giustino Varrassi, et al.
Published: (2024-12-01)

Palmitoylethanolamide exerts neuroprotective effects in mixed neuroglial cultures and organotypic hippocampal slices via peroxisome proliferator-activated receptor-α
by: Scuderi Caterina, et al.
Published: (2012-03-01)

Neuroprotection Targeting Protein Misfolding on Chronic Cerebral Hypoperfusion in the Context of Metabolic Syndrome
by: María I. Herrera, et al.
Published: (2018-05-01)

Parkinson's Disease in the Era of a Novel Respiratory Virus Pandemic
by: Matilde Otero-Losada, et al.
Published: (2020-09-01)

Effect of palmitoylethanolamide on inflammatory and neuropathic pain in rats
by: Tai-Kyung Seol, et al.
Published: (2017-10-01)

Therapeutic Potential of Palmitoylethanolamide in Gastrointestinal Disorders
by: Marija Branković, et al.
Published: (2024-05-01)

Effect of ultramicronized-palmitoylethanolamide and co-micronized palmitoylethanolamide/polydatin on chronic pelvic pain and quality of life in endometriosis patients: An open-label pilot study
by: Stochino Loi E, et al.
Published: (2019-08-01)

Therapeutic Use of Palmitoylethanolamide as an Anti-Inflammatory and Immunomodulator
by: Maria Clara Inácio de Sá, et al.
Published: (2023-12-01)

Corrigendum: Oral ultramicronized palmitoylethanolamide: plasma and tissue levels and spinal antihyperalgesic effect
by: Stefania Petrosino, et al.
Published: (2024-06-01)

Oral Ultramicronized Palmitoylethanolamide: Plasma and Tissue Levels and Spinal Anti-hyperalgesic Effect
by: Stefania Petrosino, et al.
Published: (2018-03-01)

Neuroprotection from protein misfolding in cerebral hypoperfusion concurrent with metabolic syndrome. A translational perspective
by: Sofía Bordet, et al.
Published: (2023-08-01)

Administration of palmitoylethanolamide in combination with topiramate in the preventive treatment of nummular headache
by: Chirchiglia D, et al.
Published: (2016-07-01)

Palmitoylethanolamide for sleep disturbance. A double-blind, randomised, placebo-controlled interventional study
by: Amanda Rao, et al.
Published: (2021-09-01)

Effects of the glial modulator palmitoylethanolamide on chronic pain intensity and brain function
by: Alshelh Z, et al.
Published: (2019-08-01)

Palmitoylethanolamide and White Matter Lesions: Evidence for Therapeutic Implications
by: Marta Valenza, et al.
Published: (2022-08-01)

Co-micronized palmitoylethanolamide/polydatin treatment causes endometriotic lesion regression in a rodent model of surgically-induced endometriosis
by: Rosanna Di Paola, et al.
Published: (2016-10-01)

Adipokines, Cardiovascular Risk, and Therapeutic Management in Obesity and Psoriatic Arthritis
by: Sabrina Porta, et al.
Published: (2021-02-01)

Antioxidant and Anti-Inflammatory Activity of Combined Phycocyanin and Palmitoylethanolamide in Human Lung and Prostate Epithelial Cells
by: Loredana Bergandi, et al.
Published: (2022-01-01)

Short-term efficacy of a fixed association of Palmitoylethanolamide and other phytochemicals as add-on therapy in the management of chronic pain in elderly patients: a real-world retrospective study
by: Walter Gianni, et al.
Published: (2018-05-01)

Antiepileptogenic Effect of Subchronic Palmitoylethanolamide Treatment in a Mouse Model of Acute Epilepsy
by: Julia M. Post, et al.
Published: (2018-03-01)

A randomised controlled trial assessing the potential of palmitoylethanolamide (PEA) to act as an adjuvant to resistance training in healthy adults: a study protocol
by: Zoya Huschtscha, et al.
Published: (2023-03-01)

Co-ultramicronized palmitoylethanolamide/luteolin promotes neuronal regeneration after spinal cord injury
by: Rosalia eCrupi, et al.
Published: (2016-03-01)

Oleoylethanolamide and Palmitoylethanolamide Enhance IFNβ-Induced Apoptosis in Human Neuroblastoma SH-SY5Y Cells
by: Chiara Camoglio, et al.
Published: (2024-04-01)

A Pilot Cross-Sectional Study to Investigate the Biomarker Potential of Phosphorylated Neurofilament-H and Immune Mediators of Disability in Patients With 5 Year Relapsing-Remitting Multiple Sclerosis
by: María Inés Herrera, et al.
Published: (2019-10-01)

Efficacy of Palmitoylethanolamide and Luteolin Association on Post-Covid Olfactory Dysfunction: A Systematic Review and Meta-Analysis of Clinical Studies
by: Anna Paola Capra, et al.
Published: (2023-08-01)